Endocrinologia Diabetes Y Nutricion最新文献

英文中文

Chrononutrition patterns and their association with body weight: Differences across multiple chronotypes 时间营养模式及其与体重的关系：不同时间类型的差异。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-01-01 DOI: 10.1016/j.endien.2024.12.006

Giovana Longo-Silva , Renan Serenini , Anny Pedrosa , Márcia Lima , Larissa Soares , Júlia Melo , Risia Menezes

Introduction

In recent years, the focus of research on obesity and its management has expanded beyond traditional dietary factors to include the timing of food intake – in relation to the body's circadian rhythms – known as chrononutrition. However, chrononutrition patterns remain largely unexplored in low-medium income countries. Our study aimed to investigate the association between chrononutrition patterns and BMI.

Material and methods

Utilizing data from the virtual Survey SONAR-Brazil (n = 2137,18–65 y), we defined the following chrononutrition patterns: 1. The clock time of the first, mid, and last eating events; 2. Morning and evening latencies (from wake-up time until the first eating event, and from the last eating event until bedtime); and 3. Eating window. Linear regression analyses assessed associations between chrononutrition variables and BMI. Quantile regression and restricted cubic splines were used to explore distributional correlations and association shapes.

Results

Among all participants, BMI increased with each additional hour of the first eating event (β = 0.17; 95% CI, 0.05,0.29; P = 0.005), morning latency (β = 0.27; 95% CI, 0.12,0.42; P < 0.001), and eating midpoint (β = 0.21; 95% CI, 0.05,0.38; P = 0.01) and the effect was even stronger with higher BMI percentiles. There was no effect of eating times among intermediate and late chronotypes. However, among early types, positive associations were seen between the BMI and the timing of the first eating event, morning latency, and eating midpoint, as well as a negative association with evening eating.

Conclusions

Our findings suggest that delaying the first eating event, the eating midpoint, and extending morning latency are associated with higher BMI, particularly in early chronotypes. These results highlight the importance of aligning eating patterns with chronotypes and support personalized dietary recommendations.

近年来，肥胖及其管理的研究重点已经超越了传统的饮食因素，包括食物摄入的时间-与身体的昼夜节律有关-被称为时间营养。然而，中低收入国家的时间营养模式在很大程度上仍未得到探索。我们的研究旨在调查时间营养模式与BMI之间的关系。材料和方法：利用虚拟调查SONAR-Brazil （n=2137,18-65 y）的数据，我们定义了以下时间营养模式：进餐的第一、中、末的时钟时间；2. 早晚潜伏期（从起床时间到第一次进食，从最后一次进食到就寝时间）；和3。吃窗口。线性回归分析评估了时间营养变量与BMI之间的关系。分位数回归和限制三次样条用于探索分布相关性和关联形状。结果：在所有参与者中，BMI随着第一次进食活动的每增加一小时而增加(β=0.17；95% ci, 0.05,0.29；P=0.005)，晨间潜伏期(β=0.27；95% ci, 0.12,0.42；结论：我们的研究结果表明，延迟第一次进食事件、进食中点和延长早晨潜伏期与较高的BMI有关，特别是在早期睡眠类型中。这些结果强调了使饮食模式与生物钟类型保持一致的重要性，并支持个性化的饮食建议。

{"title":"Chrononutrition patterns and their association with body weight: Differences across multiple chronotypes","authors":"Giovana Longo-Silva , Renan Serenini , Anny Pedrosa , Márcia Lima , Larissa Soares , Júlia Melo , Risia Menezes","doi":"10.1016/j.endien.2024.12.006","DOIUrl":"10.1016/j.endien.2024.12.006","url":null,"abstract":"<div><h3>Introduction</h3><div>In recent years, the focus of research on obesity and its management has expanded beyond traditional dietary factors to include the timing of food intake – in relation to the body's circadian rhythms – known as chrononutrition. However, chrononutrition patterns remain largely unexplored in low-medium income countries. Our study aimed to investigate the association between chrononutrition patterns and BMI.</div></div><div><h3>Material and methods</h3><div>Utilizing data from the virtual Survey SONAR-Brazil (<em>n</em>  =0.17; 95% CI, 0.05,0.29; <em>P</em>  =0.27; 95% CI, 0.12,0.42; <em>P</em>  =0.21; 95% CI, 0.05,0.38; <em>P</em>  <!-->0.01) and the effect was even stronger with higher BMI percentiles. There was no effect of eating times among intermediate and late chronotypes. However, among early types, positive associations were seen between the BMI and the timing of the first eating event, morning latency, and eating midpoint, as well as a negative association with evening eating.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that delaying the first eating event, the eating midpoint, and extending morning latency are associated with higher BMI, particularly in early chronotypes. These results highlight the importance of aligning eating patterns with chronotypes and support personalized dietary recommendations.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 1","pages":"Pages 4-13"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When anorexia nervosa complicates: Bezoar and gastroduodenal obstruction 神经性厌食症并发：牛黄和胃十二指肠梗阻。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-01-01 DOI: 10.1016/j.endien.2024.12.002

Vanessa Capristán-Díaz , Pablo de Sol , Juan González González , Rosalía González Miyar , Rocío Campos del Portillo

引用次数: 0

Effects of vitamin D supplementation on TSH and thyroid hormones: A systematic review of randomized controlled trials 补充维生素D对TSH和甲状腺激素的影响：随机对照试验的系统回顾。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-01-01 DOI: 10.1016/j.endien.2024.12.007

Sara Safari , Sara Shojaei-Zarghani , Roghayeh Molani-Gol , Maryam Rafraf , Mahsa Malekian

Objective

Approximately 200 million people have been diagnosed with thyroid disease worldwide. Associations between thyroid disorders and nutritional factors have been established in former studies.

Methods

The Web of Science, PubMed, and Scopus databases and Google Scholar were searched without date restriction until June 2023 by using relevant keywords. All original articles written in English that studied the effects of vitamin D supplementation on TSH and thyroid hormones were eligible for the present review.

Results

The present review included a total of 16 randomized controlled trials (RCTs) with 1127 participants (intervention group, 630; control group, 497). Based on the findings made, vitamin D supplementation had no significant effects on serum TSH levels in 9 cases (56.2%) reported in the trials. However, TSH levels were elevated in 4 studies (26.6%) and low in 3 (18.7%) cases after vitamin D administration. Four cases reported in 6 RCTs and 4 cases reported in 5 trials indicated no significant effects on thyroxine (T₄) and triiodothyronine (T₃) levels after vitamin D supplementation, respectively. Moreover, 8 cases of 11 included RCTs reported that vitamin D intake had no significant effects on fT4, and 5 cases of 7 RCTs demonstrated no significant effects on fT3 levels after vitamin D supplementation.

Conclusion

Most findings suggest that vitamin D supplementation had no significant effects on thyroid hormones and more than half indicated no significant effect on TSH levels. Nevertheless, high-quality research is further required to prove these achievements and evaluate vitamin D effects on other markers of thyroid function.

目的：全世界约有2亿人被诊断患有甲状腺疾病。甲状腺疾病和营养因素之间的联系在以前的研究中已经确立。方法：使用相关关键词检索Web of Science、PubMed、Scopus数据库和谷歌Scholar，检索日期不限，截止到2023年6月。所有研究补充维生素D对TSH和甲状腺激素影响的英文原创文章都符合本综述的要求。结果：本综述共纳入16项随机对照试验（RCTs）， 1127名受试者(干预组630名；对照组，497)。根据研究结果，在试验中报告的9例（56.2%）病例中，补充维生素D对血清TSH水平没有显著影响。然而，服用维生素D后，4例TSH水平升高（26.6%），3例TSH水平降低（18.7%）。6项随机对照试验报告的4例和5项试验报告的4例分别表明补充维生素D对甲状腺素（T4）和三碘甲状腺原氨酸（T3）水平无显著影响。此外，11例纳入的随机对照试验中有8例报告维生素D摄入对fT4没有显著影响，7例随机对照试验中有5例报告补充维生素D后对fT3水平没有显著影响。结论：大多数研究结果表明，补充维生素D对甲状腺激素没有显著影响，超过一半的研究结果表明对TSH水平没有显著影响。然而，需要进一步的高质量研究来证明这些成果，并评估维生素D对甲状腺功能其他标志物的影响。

{"title":"Effects of vitamin D supplementation on TSH and thyroid hormones: A systematic review of randomized controlled trials","authors":"Sara Safari , Sara Shojaei-Zarghani , Roghayeh Molani-Gol , Maryam Rafraf , Mahsa Malekian","doi":"10.1016/j.endien.2024.12.007","DOIUrl":"10.1016/j.endien.2024.12.007","url":null,"abstract":"<div><h3>Objective</h3><div>Approximately 200 million people have been diagnosed with thyroid disease worldwide. Associations between thyroid disorders and nutritional factors have been established in former studies.</div></div><div><h3>Methods</h3><div>The Web of Science, PubMed, and Scopus databases and Google Scholar were searched without date restriction until June 2023 by using relevant keywords. All original articles written in English that studied the effects of vitamin D supplementation on TSH and thyroid hormones were eligible for the present review.</div></div><div><h3>Results</h3><div>The present review included a total of 16 randomized controlled trials (RCTs) with 1127 participants (intervention group, 630; control group, 497). Based on the findings made, vitamin D supplementation had no significant effects on serum TSH levels in 9 cases (56.2%) reported in the trials. However, TSH levels were elevated in 4 studies (26.6%) and low in 3 (18.7%) cases after vitamin D administration. Four cases reported in 6 RCTs and 4 cases reported in 5 trials indicated no significant effects on thyroxine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) levels after vitamin D supplementation, respectively. Moreover, 8 cases of 11 included RCTs reported that vitamin D intake had no significant effects on fT4, and 5 cases of 7 RCTs demonstrated no significant effects on fT3 levels after vitamin D supplementation.</div></div><div><h3>Conclusion</h3><div>Most findings suggest that vitamin D supplementation had no significant effects on thyroid hormones and more than half indicated no significant effect on TSH levels. Nevertheless, high-quality research is further required to prove these achievements and evaluate vitamin D effects on other markers of thyroid function.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 1","pages":"Pages 37-46"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression 使用SGLT2抑制剂减少高尿酸血症事件：一项最新的meta回归系统综述。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-01-01 DOI: 10.1016/j.endien.2024.12.005

Hamlet Ghukasyan , Denilsa Dinis Pedro Navalha , Ignacio Pérez Romero , Maria Vitória Prato Wolwacz , Artur Ghahramanyan , Cristiane Wen Tsing Ngan , Maria Helena Siqueira Tavares de Melo , Caroline Serafim Dagostin , Luis Gómez-Lechón Quirós

Introduction

Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) were shown to lower hyperuricemic events in patients with type 2 diabetes mellitus (T2DM), the extent of this effect in the general population is yet to be elucidated. We performed an updated systematic review and meta-analysis on a large sample of patients with and without T2DM to evaluate the influence of SGLT2i therapy on clinically relevant hyperuricemic events, defined as the composite of acute gout flare episodes, acute anti-gout management or urate-lowering therapy initiation. Furthermore, we conducted a multivariate meta-regression to assess the relationship between different covariates and the pooled effect size.

Materials and methods

We systematically searched all reported outcomes of interest in patients on SGLT2i (PROSPERO: CRD42023442077) across PubMed, Scopus and Cochrane databases looking for randomized controlled trials, observational studies and post-hoc analyses since inception until August 2023.

Results

Data from seven randomized controlled trials and seven observational studies were included for a total of 464,009 patients, 13,370 of whom did not have T2DM. A total of 50% of the patients included were on SGLT2i. The pooled analysis demonstrated that SGLT2i reduce clinically relevant hyperuricemic events by 33% (HR, 0.67; 95% CI, 0.59–0.77; I² = 83%) regardless of the concomitant diagnosis of T2DM. The multivariate meta-regression on chronic kidney disease (CKD) showed a positive correlation on the pooled effect size.

Conclusions

SGLT2i reduce the risk of developing hyperuricemic events regardless of the concomitant diagnosis of T2DM. The multivariate meta-regression on CKD showed a significant impact on the main outcome. Further studies are essential to investigate more conclusively the extent of these beneficial effects.

虽然钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i）被证明可以降低2型糖尿病（T2DM）患者的高尿酸血症事件，但这种作用在一般人群中的程度尚未阐明。我们对大量T2DM患者和非T2DM患者进行了最新的系统回顾和荟萃分析，以评估SGLT2i治疗对临床相关高尿酸血症事件的影响，高尿酸血症事件定义为急性痛风发作、急性抗痛风管理或降尿酸治疗开始的组合。此外，我们进行了多元元回归来评估不同协变量与合并效应大小之间的关系。材料和方法：我们系统地检索了PubMed、Scopus和Cochrane数据库中关于SGLT2i （PROSPERO: CRD42023442077）患者的所有报告结果，寻找自成立以来至2023年8月的随机对照试验、观察性研究和事后分析。结果：7项随机对照试验和7项观察性研究的数据共纳入464,009例患者，其中13,370例无T2DM。总共有50%的患者接受SGLT2i治疗。合并分析表明，SGLT2i可减少33%的临床相关高尿酸血症事件(HR, 0.67；95% ci, 0.59-0.77；I2=83%)，无论是否伴有T2DM。慢性肾脏疾病（CKD）的多变量meta回归显示合并效应量呈正相关。结论：SGLT2i降低了发生高尿酸血症事件的风险，无论是否伴有T2DM。CKD的多变量meta回归显示对主要结局有显著影响。为了更确切地调查这些有益影响的程度，有必要进行进一步的研究。

{"title":"Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression","authors":"Hamlet Ghukasyan , Denilsa Dinis Pedro Navalha , Ignacio Pérez Romero , Maria Vitória Prato Wolwacz , Artur Ghahramanyan , Cristiane Wen Tsing Ngan , Maria Helena Siqueira Tavares de Melo , Caroline Serafim Dagostin , Luis Gómez-Lechón Quirós","doi":"10.1016/j.endien.2024.12.005","DOIUrl":"10.1016/j.endien.2024.12.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) were shown to lower hyperuricemic events in patients with type 2 diabetes mellitus (T2DM), the extent of this effect in the general population is yet to be elucidated. We performed an updated systematic review and meta-analysis on a large sample of patients with and without T2DM to evaluate the influence of SGLT2i therapy on clinically relevant hyperuricemic events, defined as the composite of acute gout flare episodes, acute anti-gout management or urate-lowering therapy initiation. Furthermore, we conducted a multivariate meta-regression to assess the relationship between different covariates and the pooled effect size.</div></div><div><h3>Materials and methods</h3><div>We systematically searched all reported outcomes of interest in patients on SGLT2i (PROSPERO: CRD42023442077) across PubMed, Scopus and Cochrane databases looking for randomized controlled trials, observational studies and post-hoc analyses since inception until August 2023.</div></div><div><h3>Results</h3><div>Data from seven randomized controlled trials and seven observational studies were included for a total of 464,009 patients, 13,370 of whom did not have T2DM. A total of 50% of the patients included were on SGLT2i. The pooled analysis demonstrated that SGLT2i reduce clinically relevant hyperuricemic events by 33% (HR, 0.67; 95% CI, 0.59–0.77; <em>I</em><sup>2</sup>  <!-->83%) regardless of the concomitant diagnosis of T2DM. The multivariate meta-regression on chronic kidney disease (CKD) showed a positive correlation on the pooled effect size.</div></div><div><h3>Conclusions</h3><div>SGLT2i reduce the risk of developing hyperuricemic events regardless of the concomitant diagnosis of T2DM. The multivariate meta-regression on CKD showed a significant impact on the main outcome. Further studies are essential to investigate more conclusively the extent of these beneficial effects.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 1","pages":"Pages 26-36"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rhinocerebral mucormycosis: an uncommon complication in patients with diabetes mellitus 鼻-脑毛霉病：糖尿病患者中一种罕见的并发症。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-01-01 DOI: 10.1016/j.endien.2024.12.003

Sara Rodríguez Arboleya , Lucía Díaz Naya , Raquel Fernández Morais , María Sagrario Santos Seoane , María Pasarón Fernández

引用次数: 0

Phase angle: Differences between disease-related malnutrition, obesity and healthy people 相角：与疾病相关的营养不良、肥胖和健康人群之间的差异。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2024-12-01 DOI: 10.1016/j.endien.2024.07.003

Mario A. Saavedra Vásquez , Javier Castañón Alonso , Begoña Pintor de la Maza , Elena González Arnáiz , Diana García Sastre , Diana G. Ariadel Cobo , Ana M. Urioste Fondo , María Antequera González , María del Carmen Dameto Pons , María D. Ballesteros Pomar

Introduction

Bioelectrical Impedance Analysis (BIA) is a tool used in clinical nutrition and pure electrical data such as phase angle (PA) has shown prognostic value. It relates resistance and reactance indicating cellular health.

Objective

To determine differences in PA between patients with obesity and disease-related malnutrition (DRM) compared to the healthy population, and to establish associations between PA and other body composition (BC) parameters.

Materials and methods

Retrospective observational study with 1079 patients from the Obesity and Nutrition Department of the Complejo Asistencial Universitario de León between April/2014 and August/2022 as well as 86 healthy controls. Demographic and anthropometric variables were collected and BC was performed with BIA Tanita MC780®. Diagnosis of malnutrition according to GLIM criteria and obesity with body mass index (BMI).

Results

PA50KHz in obesity group is 5.98º, DRM 4.79º and control group 6.08º. Statistically significant differences in PA between DRM and control groups, as well as DRM and obesity (p < 0.001). Weak positive correlation in total population (r = 0.452, p < 0.001) as well as control group (r = 0.463, p < 0.001) between BMI and PA. Weak negative correlation in the total population (r = −0.408, p < 0.001), DRM (r = −0.268, p < 0.001) and obesity (r = −0.342, p < 0.001) between age and PA.

Conclusions

In this study, significantly lower PA was observed in the DRM group than in the control and obesity groups. No statistically significant differences between PA in the obesity and control groups and no correlation between BMI and PA in the obesity group. More studies are needed to standardize cut-off points in different contexts and populations.

简介生物电阻抗分析（BIA）是临床营养学中使用的一种工具，相位角（PA）等纯电数据具有预后价值。它将电阻和电抗联系起来，显示细胞的健康状况：确定肥胖症和疾病相关营养不良（DRM）患者与健康人群相比在 PA 方面的差异，并确定 PA 与其他身体成分（BC）参数之间的关联：2014年4月至2022年8月期间，对莱昂大学综合医院肥胖与营养科的1079名患者以及86名健康对照者进行了回顾性观察研究。研究人员收集了人口统计学和人体测量变量，并使用 BIA Tanita MC780® 进行了 BC 分析。根据 GLIM 标准诊断营养不良，根据体重指数（BMI）诊断肥胖：结果：肥胖组的 PA50KHz 为 5.98º，DRM 为 4.79º，对照组为 6.08º。DRM 组和对照组以及 DRM 组和肥胖组之间的 PA 差异具有统计学意义（p 结论：肥胖组的 PA50KHz 明显低于 DRM 组：在本研究中，DRM 组的 PA 明显低于对照组和肥胖组。肥胖组和对照组的 PA 没有明显的统计学差异，肥胖组的 BMI 和 PA 之间也没有相关性。需要进行更多的研究，以便在不同的环境和人群中统一截断点。

{"title":"Phase angle: Differences between disease-related malnutrition, obesity and healthy people","authors":"Mario A. Saavedra Vásquez , Javier Castañón Alonso , Begoña Pintor de la Maza , Elena González Arnáiz , Diana García Sastre , Diana G. Ariadel Cobo , Ana M. Urioste Fondo , María Antequera González , María del Carmen Dameto Pons , María D. Ballesteros Pomar","doi":"10.1016/j.endien.2024.07.003","DOIUrl":"10.1016/j.endien.2024.07.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Bioelectrical Impedance Analysis (BIA) is a tool used in clinical nutrition and pure electrical data such as phase angle (PA) has shown prognostic value. It relates resistance and reactance indicating cellular health.</div></div><div><h3>Objective</h3><div>To determine differences in PA between patients with obesity and disease-related malnutrition (DRM) compared to the healthy population, and to establish associations between PA and other body composition (BC) parameters.</div></div><div><h3>Materials and methods</h3><div>Retrospective observational study with 1079 patients from the Obesity and Nutrition Department of the Complejo Asistencial Universitario de León between April/2014 and August/2022 as well as 86 healthy controls. Demographic and anthropometric variables were collected and BC was performed with BIA Tanita MC780®. Diagnosis of malnutrition according to GLIM criteria and obesity with body mass index (BMI).</div></div><div><h3>Results</h3><div>PA50KHz in obesity group is 5.98º, DRM 4.79º and control group 6.08º. Statistically significant differences in PA between DRM and control groups, as well as DRM and obesity (<em>p</em> < 0.001). Weak positive correlation in total population (<em>r</em> = 0.452, <em>p</em> < 0.001) as well as control group (<em>r</em> = 0.463, <em>p</em> < 0.001) between BMI and PA. Weak negative correlation in the total population (<em>r</em> = −0.408, <em>p</em> < 0.001), DRM (<em>r</em> = −0.268, <em>p</em> < 0.001) and obesity (<em>r</em> = −0.342, <em>p</em> < 0.001) between age and PA.</div></div><div><h3>Conclusions</h3><div>In this study, significantly lower PA was observed in the DRM group than in the control and obesity groups. No statistically significant differences between PA in the obesity and control groups and no correlation between BMI and PA in the obesity group. More studies are needed to standardize cut-off points in different contexts and populations.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 10","pages":"Pages 421-426"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Micro solutions for macro problems: Challenging thyroid and parathyroid function tests 宏观问题的微观解决方案：挑战甲状腺和甲状旁腺功能测试

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2024-12-01 DOI: 10.1016/j.endien.2024.11.013

Utku Soyaltin , Ayla Yildiz , Nurhilal Yusufoğlu , Emre İspir

引用次数: 0

Super response to liraglutide in people with obesity: A case report and literature review 肥胖患者对利拉鲁肽的超级反应：1例报告和文献综述

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2024-12-01 DOI: 10.1016/j.endien.2024.11.012

Sonsoles Gutiérrez Medina , Elena Sánchez Campayo , Sonsoles Guadalix , Javier Escalada

GLP1 receptor agonists (GLP1-RAs) are currently the most widely used pharmacological option to treat obesity. However, considerable heterogeneity in weight loss response has been observed with different anti-obesity drugs and response predictors to these drugs still remain ambiguous. Furthermore, very few published data have been available on cases of high-responders to treatment with GLP1-RAs. In this article, we present the case of a patient with grade 4 obesity (initial body mass index, 50.2 kg/m²) with associated mechanical and metabolic complications who achieved an initial weight loss of 40% at 1 year with hygienic-dietary measures and drug treatment with liraglutide. We also review the available literature on factors potentially contributing to variations in weight loss with GLP1-RAs in general and liraglutide, in particular.

GLP1受体激动剂（GLP1- ras）是目前治疗肥胖最广泛使用的药物选择。然而，不同的抗肥胖药物在减肥反应方面存在相当大的异质性，这些药物的反应预测因素仍然不明确。此外，很少有已发表的关于GLP1-RAs治疗高反应病例的数据。在这篇文章中，我们报告了一例4级肥胖患者（初始体重指数为50.2 kg/m2），伴有相关的机械和代谢并发症，通过卫生饮食措施和利拉鲁肽药物治疗，患者在一年内体重减轻了40%。我们还回顾了现有文献中可能导致GLP1-RAs和利拉鲁肽减肥变化的因素。

引用次数: 0

Are we underdiagnosing cognitive impairment in patients with type 2 diabetes mellitus? 我们是否对 2 型糖尿病患者的认知障碍诊断不足？

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2024-12-01 DOI: 10.1016/j.endien.2024.11.009

Antelm Pujol , Pilar Sanchis , María I. Tamayo , Lluís Masmiquel

引用次数: 0

Thyroid and assisted reproduction 甲状腺与辅助生殖

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2024-12-01 DOI: 10.1016/j.endien.2024.10.002

Gemma Sesmilo

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Endocrinologia Diabetes Y Nutricion

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀